In addition to lowering LDL-C, alirocumab is associated with which modest lipid change?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

In addition to lowering LDL-C, alirocumab is associated with which modest lipid change?

Alirocumab’s primary action is to lower LDL-C by increasing hepatic LDL receptor recycling, which clears more LDL from the blood. Beyond this strong LDL-C effect, trials consistently show only a small rise in HDL-C with PCSK9 inhibitors like alirocumab. The increase in HDL-C is modest, not dramatic, and triglyceride levels don’t swing by large amounts. So the most accurate statement is that alirocumab is associated with a modest increase in HDL-C.

Alirocumab’s primary action is to lower LDL-C by increasing hepatic LDL receptor recycling, which clears more LDL from the blood. Beyond this strong LDL-C effect, trials consistently show only a small rise in HDL-C with PCSK9 inhibitors like alirocumab. The increase in HDL-C is modest, not dramatic, and triglyceride levels don’t swing by large amounts. So the most accurate statement is that alirocumab is associated with a modest increase in HDL-C.

More practice questions